Treatment of uric acid nephropathy with integrated traditional Chinese and western medicine

doi:10.3877/cma.j.issn.2095-3216.2015.02.003

Abstract

Abstract:

With the development of economy and society, and the improvement of people′s living standard, the prevalence of hyperuricemia increases year by year in China, which can cause multiple organ damage. Uric acid nephropathy is a disease due to deposit of urate crystals in the kidney. At present, integrated traditional Chinese medicine and western medicine have been used in the treatment of uric acid nephropathy. In western medicine, hyperuricemia can be ameliorated by inhibiting uric acid synthesis, promoting excretion of uric acid, and suppressing inflammation, and so on. Uricase is a new class of drugs to reduce uric acid in recent years, including rasburicase and PEG-uricase. Single agents of traditional Chinese medicine, such as iridiod glycosides from paederia scandens, ethanol extract of rhizoma smilasic chinae, quercetin, and rutin, have positive roles in relieving hyperuricemia and protecting kidney. Compounds of traditional Chinese medicine, including Ermiao pill, Simiao decoction, and Siwu decoction combined with Ermiao powder can inhibit the hyperuricemia so as to improve renal function. Therefore, integrated traditional Chinese medicine and western medicine are important in the treatment of uric acid nephropathy.

Key words: Hyperuricemia, Uric acid nephropathy, Integrated traditional Chinese and western medicine, Treatment

Niansong Wang. Treatment of uric acid nephropathy with integrated traditional Chinese and western medicine[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2015, 04(02): 69-73.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2015.02.003

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2015/V04/I02/69

References 25

[1]	Moran ME. Uric acid stone disease [J]. Front Biosci, 2003, 1(8): S1339-S1355.
[2]	李迎巧，高建东. 尿酸性肾病的中医药防治研究进展[J]. 中国中西医结合肾病杂志，2014，15(3)：270-272.
[3]	Ben-Dov IZ, Kark JD. Serum uric acid is a GFR-independent long-term predictor of acute and chronic renal insufficiency: the Jerusalem Lipid Research Clinic cohort study [J]. Nephrol Dial Transplant, 2011, 26(8): 2558-2566.
[4]	中华医学会内分泌学分会．高尿酸血症和痛风治疗的中国专家共识[J]．中华内分泌代谢杂志，2013，29(11)：913-920.
[5]	刘慧. 新型降尿酸药非布索坦的临床研究进展[J]. 中国医药科学，2013，3(13)：37-39.
[6]	姚远兵，王玲，夏悦，等. 新型抗痛风药物非布索坦概述[J]. 中国药师，2012，15(6)：886-889.
[7]	王丽英，赵燕，郑毅，等. 随机双盲三模拟对照多中心临床研究非布索坦降低痛风患者高尿酸水平的疗效和安全性[J/CD]. 中华临床医师杂志(电子版), 2013，7(7)：2798-2803.
[8]	傅毅. 高尿酸血症治疗药拉布立酶(rasburicase)[J]. 国外医药(合成药、生化药、制剂分册)，2002，23(6)：383-384.
[9]	Pui CH. Rasburicase: a potent uricolytic agent [J]. Expert Opin Pharmacother, 2002, 3(4): 433-442.
[10]	王成君. 新型抗痛风药物-Pegloticase[J]. 医药导报，2012，31(9)：1188-1189.
[11]	刘霞，祁兢晶. 秋水仙碱脂质体凝胶对痛风模型动物的抗炎作用[J]. 广东医学，2011，32(23)：3038-3040.
[12]	Ararat E, Brozovich FV. Losartan decreases p42/44 MAPK signaling and preserves LZ＋MYPT 1 expression [J]. PLoS One, 2009, 4(4)：e5144.
[13]	肖祖容，苏军霞，李建华，等．尿酸性肾病的治疗进展[J]．甘肃科技纵横，2011，40(4)：191-193.
[14]	Uchida S, Takahashi M, Sugawara M, et al. Effects of the N/L-type calcium channel blocker cilnidipine on nephropathy and uric acid metabolism in hypertensive patients with chronic kidney disease (J-CIRCLE Study) [J]. J Clin Hypertens (Greenwich), 2014, 16(10): 746-753.
[15]	金辉，庞明群，苏宇，等. 鸡矢藤环烯醚萜苷对尿酸性肾病大鼠的防治作用[J]. 安徽医科大学学报，2011，46(10)：1026-1028.
[16]	Hou SX, Zhu WJ, Pang MQ, et al. Protective effect of iridoid glycosides from Paederia scandens (LOUR.) MERRILL (Rubiaceae) on uric acid nephropathy rats induced by yeast and potassium oxonate [J]. Food Chem Toxicol, 2014, 64: 57-64.
[17]	中华人民共和国药典委员会．中国药典(一部) [M]．北京：化学工业出版社，2005：216-217.
[18]	邓家刚，陈壮. 金刚藤活性成分与药效学及临床应用研究[J]. 河南中医学院学报，2005，20(3)：23-24.
[19]	Chen L, Yin H, Lan Z, et al. Anti-hyperuricemic and nephroprotective effects of Smilax china L [J]. J Ethnopharmacol, 2011, 135(2): 399-405.
[20]	Wang C, Pan Y, Zhang QY, et al. Quercetin and allopurinol ameliorate kidney injury in STZ-treated rats with regulation of renal NLRP3 inflammasome activation and lipid accumulation [J]. PloS One, 2012, 7(6): e38285.
[21]	Zhu JX, Wang Y, Kong LD, et al. Effects of Biota orientalis extract and its flavonoid constituents, quercetin and rutin on serum uric acid levels in oxonate-induced mice and xanthine dehydrogenase and xanthine oxidase activities in mouse liver [J]. J Ethnopharmacol, 2004, 93(1): 133-140.
[22]	Kong LD, Yang C, Ge F, et al. A Chinese herbal medicine Ermiao wan reduces serum uric acid level and inhibits liver xanthine dehydrogenase and xanthine oxidase in mice [J]. J Ethnopharmacol, 2004, 93(2-3): 325-330.
[23]	Hu QH, Jiao RQ, Wang X, et al. Simiao pill ameliorates urate underexcretion and renal dysfunction in hyperuricemic mice [J]. J Ethnopharmacol, 2010, 128(3): 685-692.
[24]	Hua J, Huang P, Zhu CM, et al. Anti-hyperuricemic and nephroprotective effects of Modified Simiao Decoction in hyperuricemic mice [J]. J Ethnopharmacol, 2012, 142(1): 248-252.
[25]	蒋茜，郭永平，王毅兴，等. 四物汤合二妙散降低高尿酸血症大鼠血尿酸水平的实验研究[J]. 中国中西医结合肾病杂志，2012，13(4)：336-338.

Please choose a citation manager

Content to export